Nori Ebersole
Director/Board Member at SIENTRA, INC.
Net worth: 1 090 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| James Robinson | M | 54 |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 5 years |
| James Hindman | M | 63 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 36 years |
| Sef P. Kurstjens | M | 60 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 10 years |
| Caroline F. van Hove | F | 43 | 21 years | |
| Philippe Schaison | M | 62 | 11 years | |
| Myrtle Potter | F | 65 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 years |
| Ronald Menezes | M | 61 | 4 years | |
| Pierre Legault | M | 63 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 years |
| Cornelia Haag-Molkenteller | M | 66 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 17 years |
| Shigeyuki Nishinaka | M | 59 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 5 years |
| Timothy Kirk Andrews | M | 45 | 10 years | |
| Ryan Kubota | M | - | - | |
| Irina Erenburg | M | 54 | 3 years | |
| Denise Dajles | F | - | 3 years | |
| Lisa Metzner | F | 55 | 10 years | |
| Rita Karachun | F | 63 | 1 years | |
| Oliver Bennett | M | 47 | 9 years | |
| Christine Ocampo | F | 51 | - | |
| Mary Fisher | F | 62 | 5 years | |
| Andrew Schmidt | M | 62 | 3 years | |
| Alexander Casdin | M | 56 | 1 years | |
| Brian R. Schaefgen | M | 53 |
Big Brothers Big Sisters of Orange County
| - |
| Vika Brough | F | - | - | |
| Christropher Doughty | M | - | 3 years | |
| Allison Luo | M | 50 | 6 years | |
| Matt Hostetler | M | - | 2 years | |
| John Lenell | M | - |
Big Brothers Big Sisters of Orange County
| - |
| Olivier Laurent | M | 52 | 4 years | |
| Brian Stevens | M | 51 |
Big Brothers Big Sisters of Orange County
| 12 years |
| Jon Filderman | M | - | 1 years | |
| Jeffrey Jones | M | - | 5 years | |
| Timothy Ryan | M | - |
Big Brothers Big Sisters of Orange County
| - |
| Vincent E. Mudd | M | - |
Big Brothers Big Sisters of Orange County
| - |
| Patrick Maciariello | M | - |
Big Brothers Big Sisters of Orange County
| - |
| Dan Carlisle | M | - | 17 years | |
| Jim Hindman | M | - |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 4 years |
| Aaron Rosenberg | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Douglas Ingram | M | 61 | 19 years | |
| Keith Katkin | M | 52 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 3 years |
| Ambrose Bailey | M | 60 | 6 years | |
| David Hovland | M | - | 15 years | |
| Mark Mckenna | M | 48 | 4 years | |
| Paul Bisaro | M | 63 | 5 years | |
| Peter John McDonnell | M | 66 | 7 years | |
| Scott Giacobello | M | 54 | 7 years | |
| Jeffrey Edwards | M | 64 | 22 years | |
| Brenton Saunders | M | 56 | 6 years | |
| Michael R. Gallagher | M | 77 | 2 years | |
| Maria Hilado | F | 59 | 4 years | |
| Keith Sullivan | M | 65 | 6 years | |
| Bryan E. Smith | M | 45 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 10 years |
| Nicholas Simon | M | 67 | 14 years | |
| Herb Boyer | M | 87 | 19 years | |
| David Pyott | M | 70 | 17 years | |
| Sanjiv Patel | M | 50 | 11 years | |
| Vivid Sehgal | M | 56 | 8 years | |
| David Adam Buchen | M | 59 | 1 years | |
| Jonathon Kellerman | M | - | 6 years | |
| Deborah Bettencourt | F | - | 15 years | |
| Judith Swain | M | 75 | 2 years | |
| J. Michael Judy | M | - | 8 years | |
| Nesli Basgoz | M | 66 | 6 years | |
| C. Nicholson | M | 68 | 6 years | |
| Matthew Joseph Maletta | M | 52 | - | |
| Helen Adams | F | 65 | 2 years | |
| Martin Hendrix | M | 56 | 3 years | |
| Noël Kurdi | F | - | 2 years | |
| Roger J. Lias | M | 63 | 6 years | |
| Keith Marshall | M | 56 | 3 years | |
| David Hollander | M | 50 | - | |
| Michael McFadden | M | 57 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 1 years |
| John Kelly | M | 57 | 6 years | |
| Les Kaplan | M | 73 | 21 years | |
| Joseph Papa | M | 68 | 3 years | |
| Sigurdur Olafsson | M | 55 | 4 years | |
| Eric Brandt | M | 62 | 6 years | |
| Leonard Schaeffer | M | 78 | 18 years | |
| Andrew L. Turner | M | 77 | 2 years | |
| Christopher Coughlin | M | 71 | 6 years | |
| James H. Bloem | M | 73 | 5 years | |
| John A. King | M | 74 | 2 years | |
| Christopher Bodine | M | 68 | 11 years | |
| Robert Todd Joyce | M | 66 | 1 years | |
| Roy J. Wilson | M | 68 | - | |
| Trevor Jones | M | 82 | 11 years | |
| Patrick O’Sullivan | M | 82 | 5 years | |
| George Frederick Wilkinson | M | 68 | 1 years | |
| Jirí Michal | M | 71 | 2 years | |
| Louis Lavigne | M | 75 | 10 years | |
| Catherine Klema | F | 65 | 15 years | |
| Fred G. Weiss | M | 82 | 18 years | |
| Kevin O'Boyle | M | 68 | 9 years | |
| Tamar Howson | F | 75 | 9 years | |
| Dawn Hudson | F | 66 | 6 years | |
| Aimee Weisner | F | 55 | 4 years | |
| Louis T. Rosso | M | - | 16 years | |
| Valerie J. Miller | F | 60 | 5 years | |
| Hafrun Fridriksdottir | M | 62 | 14 years | |
| Mary Szela | F | 60 | 2 years | |
| David Berk | M | 45 | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 74 | 74.00% |
| Ireland | 33 | 33.00% |
| Bermuda | 13 | 13.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Nori Ebersole
- Personal Network